Patents Assigned to Meiji Seika Pharma Co., Ltd.
-
Publication number: 20140303375Abstract: A process for preparing the compound of the following formula (E): wherein Bn represents a benzyl group, and tBu represents a tert-butyl group, the process including: (a) subjecting the following compound (B) to trifluoroacetylation, wherein tBu represents a tert-butyl group to produce the following compound (C): wherein tBu represents a tert-butyl group, and TFA represents a trifluoroacetyl group; (b) reacting the compound (C) with benzyloxyamine in the presence of a hydroxyl group activating agent to produce the following compound (D): wherein Bn represents a benzyl group, tBu represents a tert-butyl group, and TFA represents a trifluoroacetyl group; and (c) subjecting the compound (D) to detrifluoroacetylation.Type: ApplicationFiled: May 27, 2014Publication date: October 9, 2014Applicant: Meiji Seika Pharma. Co., Ltd.Inventors: Takao ABE, Masayuki OKUE, Yoshiaki SAKAMAKI
-
Patent number: 8853414Abstract: Disclosed is a process for efficiently producing pyripyropene derivatives having acyloxy at the 1-position and 11-position and hydroxyl at the 7-position. The process comprises selectively acylating hydroxyl at the 1-position and 11-position of a compound represented by formula B1 through one to three steps with an acylating agent in the presence or absence of a base.Type: GrantFiled: November 10, 2010Date of Patent: October 7, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Yoshimasa Fukuda, Takashi Ando, Kimihiko Goto, Nozomu Nakanishi, Takashi Watanabe, Kenichi Kurihara, Nobuto Minowa, Masaaki Mitomi
-
Patent number: 8853413Abstract: Disclosed is a process for efficiently producing pyripyropene derivatives having acyloxy at the 1-position and 11-position and hydroxyl at the 7-position. The process comprises selectively acylating hydroxyl at the 1-position and 11-position of a compound represented by formula B1 through one to three steps with an acylating agent in the presence or absence of a base.Type: GrantFiled: May 12, 2010Date of Patent: October 7, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Yoshimasa Fukuda, Takashi Ando, Kimihiko Goto, Nozomu Nakanishi, Takashi Watanabe, Kenichi Kurihara, Nobuto Minowa, Masaaki Mitomi
-
Patent number: 8822501Abstract: Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:Type: GrantFiled: January 3, 2013Date of Patent: September 2, 2014Assignees: Meiji Seika Pharma Co., Ltd., The Kitasato InstituteInventors: Kimihiko Goto, Ryo Horikoshi, Mariko Tsuchida, Kazuhiko Oyama, Satoshi Omura, Hiroshi Tomoda, Toshiaki Sunazuka
-
Patent number: 8796005Abstract: A method for suppressing a reduction in an endoglucanase activity in the presence of a surfactant, characterized by modifying a protein having the endoglucanase activity in which the N-terminus is an amino acid other than pyroglutamic acid, to a protein having the N-terminus of pyroglutamic acid, is disclosed. Further, a modified protein having an endoglucanase activity wherein the N-terminal amino acid is converted into pyroglutamic acid by an amino acid modification, a polynucleotide encoding the protein, an expression vector comprising the polynucleotide, a host cell transformed with the expression vector, and a process for producing the protein by cultivating the host cell, are disclosed.Type: GrantFiled: September 19, 2013Date of Patent: August 5, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Manabu Watanabe, Koji Yanai, Yumiko Tsuyuki
-
Publication number: 20140213791Abstract: To supply a derivative having a 2-acyliminopyridine structure and being represented by the following formula (I) in an amount required as a pest control agent stably and at a low cost, provided is a method comprising the steps of: acylating an amino group at position 2 of a compound represented by formula (A) by use of an acylating agent, to thereby produce a compound represented by formula (B); and further alkylating a nitrogen atom at position 1 of the compound represented by formula (B): [where Ar represents a phenyl group or a 5-to 6-membered heterocycle, R1 represents a C1-6 alkyl group, and Y represents a hydrogen atom; a halogen atom; a hydroxyl group; a C1-6 alkyl group which may be substituted with a halogen atom; a C1-6 alkyloxy group which may be substituted with a halogen atom; a cyano group; a formyl group; or a nitro group].Type: ApplicationFiled: August 24, 2012Publication date: July 31, 2014Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Nozomu Nakanishi, Yoshimasa Fukuda, Shigeki Kitsuda, Ikuya Ohno
-
Patent number: 8772490Abstract: Provided are an optically active diazabicyclooctane derivative defined by formula (F) below, which is useful as a pharmaceutical intermediate for ?-lactamase inhibitor, and a process for preparing the same. In formula (F) above, R1 represents CO2R, CO2M, or CONH2, wherein R represents a methyl group, a tert-butyl group, an allyl group, a benzyl group, or a 2,5-dioxopyrrolidin-1-yl group, and M represents a hydrogen atom, an inorganic cation, or an organic cation; and R2 represents a benzyl group or an allyl group.Type: GrantFiled: June 30, 2011Date of Patent: July 8, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Takao Abe, Masayuki Okue, Yoshiaki Sakamaki
-
Publication number: 20140142289Abstract: An isolated novel polynucleotide comprising a nucleotide sequence encoding at least one polypeptide involved in biosynthesis of pyripyropene A, a recombinant vector comprising the polynucleotide and a transformant comprising the polynucleotide are disclosed. By the present invention, a pyripyropene A biosynthetic gene useful for production of a novel pyripyropene analog, improvement of productivity of a pyripyropene A-producing bacterium, production of an insecticidal agent for microorganisms, creation of a plant resistant to insect pests or the like are provided.Type: ApplicationFiled: September 10, 2013Publication date: May 22, 2014Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Hiroyuki ANZAI, Kentaro YAMAMOTO, Mariko TSUCHIDA, Kazuhiko OYAMA, Masaaki MITOMI
-
Patent number: 8728794Abstract: The present invention provides a novel bacterial cell composition which comprises cells of Butyrivibrio fibrisolvens having the ability to produce butyric acid, a cultured material thereof or an extract thereof, and a method for inhibiting carcinogenesis, a method for immunostimulating, a method for preventing or treating a pathogen, a method for preventing or treating an inflammatory bowel disease and a method for preventing or treating an allergic disease, which use the same.Type: GrantFiled: December 28, 2005Date of Patent: May 20, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Takehiro Miwa, Hiroshi Watanabe, Mamoru Ishihara, Tsuneo Hino, Narito Asanuma
-
Patent number: 8710198Abstract: Caprazene is provided which is the compound represented by the following formula (I) wherein Me stands for methyl group, and a 5?-N-alkoxycarbonyl or 5?-N-aralkyloxycarbonyl derivative thereof, and wherein said compound has the 1H-NMR and 13C-NMR data as set forth in Table 15.Type: GrantFiled: December 29, 2008Date of Patent: April 29, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Toshiaki Miyake, Masayuki Igarashi, Tetsuo Shitara, Yoshiaki Takahashi, Masa Hamada
-
Patent number: 8697409Abstract: Disclosed are a ketoreductase mutant which can be used for an efficient production of daunorubicin derivatives, a DNA encoding the mutant, a transformant prepared by introducing the DNA thereinto to produce a daunorubicin derivative, and a process of producing a daunorubicin derivative using the transformant. The ketoreductase mutant has an amino acid sequence in which one amino acid residue or two or more amino acid residues selected from the group consisting of amino acids located at positions corresponding to the 42nd, 149th, 153rd, 270th, and 306th amino acids in the amino acid sequence of a ketoreductase (EvaE) from a chlororemomycin-producing bacterium (Amycolatopsis orientalis) are substituted with another amino acid residues.Type: GrantFiled: May 21, 2010Date of Patent: April 15, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Fusuke Mazuka, Takayoshi Fukushima, Naomi Sumida, Koji Yanai
-
Patent number: 8697382Abstract: An object of the present invention is to provide a method of identifying metallo-?-lactamase-producing bacteria, particularly, a method of conveniently identifying an IMP or VIM type. According to the present invention, there is provided a method of detecting metallo-?-lactamase-producing bacteria, comprising spotting a compound (I) onto a surface of a solid medium coated with the bacteria to be tested, spotting 3 types of ?-lactam agents at 3 respective positions different from the spot of the compound (I), culturing the solid medium, and then detecting the metallo-?-lactamase-producing bacteria based on the shape of an inhibition zone formed around the spot of each of the ?-lactam agents. There is further provided a method of identifying an IMP or VIM type of the metallo-?-lactamase-producing bacteria.Type: GrantFiled: March 31, 2010Date of Patent: April 15, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventor: Akihiro Morinaka
-
Publication number: 20140051147Abstract: A method for suppressing a reduction in an endoglucanase activity in the presence of a surfactant, characterized by modifying a protein having the endoglucanase activity in which the N-terminus is an amino acid other than pyroglutamic acid, to a protein having the N-terminus of pyroglutamic acid, is disclosed. Further, a modified protein having an endoglucanase activity wherein the N-terminal amino acid is converted into pyroglutamic acid by an amino acid modification, a polynucleotide encoding the protein, an expression vector comprising the polynucleotide, a host cell transformed with the expression vector, and a process for producing the protein by cultivating the host cell, are disclosed.Type: ApplicationFiled: September 19, 2013Publication date: February 20, 2014Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Manabu WATANABE, Koji YANAI, Yumiko TSUYUKI
-
Publication number: 20140046043Abstract: A macrolide compound represented by the formula (I) effective against erythromycin resistant bacteria (for example, resistant pneumococci, streptococci and mycoplasmas).Type: ApplicationFiled: February 20, 2012Publication date: February 13, 2014Applicants: MEIJI SEIKA PHARMA CO., LTD., TAISHO PHARMACEUTICAL CO., LTD.Inventors: Tomohiro Sugimoto, Naoki Sasamoto, Jun Kurosaka, Masato Hayashi, Kanako Yamamoto, Masato Kashimura, Yasunobu Ushiki, Haruhisa Ogita, Tomoaki Miura, Kenichi Kanemoto, Kou Kumura, Satoshi Yoshida, Keiji Tamura, Eiki Shitara
-
Publication number: 20140045778Abstract: Disclosed is a composition for use as a pest control agent, comprising a compound represented by formula (I) or an agriculturally and horticulturally acceptable salt thereof as active ingredient and an agriculturally and horticulturally acceptable carrier:Type: ApplicationFiled: January 3, 2013Publication date: February 13, 2014Applicants: THE KITASATO INSTITUTE, MEIJI SEIKA PHARMA CO., LTD.Inventors: MEIJI SEIKA PHARMA CO., LTD., THE KITASATO INSTITUTE
-
Patent number: 8648065Abstract: An objective of the present invention is to provide a cefditoren pivoxil pharmaceutical preparation which can safely be administered to a patient and not only improves wettability of cefditoren pivoxil, but also further improves absorbability through the intestinal tracts by maintaining amorphous particles having a high oral absorbability in a liquid for a long period of time. The present invention is a pharmaceutical composition comprising amorphous cefditoren pivoxil and a sucrose fatty acid ester, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sucrose fatty acid ester while amorphous cefditoren pivoxil maintains its particle state.Type: GrantFiled: April 28, 2003Date of Patent: February 11, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Yukiko Yokoi, Shigeru Chikase, Hiroyuki Yamaguchi
-
Patent number: 8648195Abstract: An objective of the present invention is to provide a crystal of 2-ethyl-3,7-dimethyl-6-(4-(trifluoromethoxy)phenoxy)quinoline-4-yl methyl carbonate having stable physicochemical properties. The objective is attained by a crystal of 2-ethyl-3,7-dimethyl-6-(4-(trifluoromethoxy)phenoxy)quinoline-4-yl methyl carbonate that exhibits a diffraction peak pattern shown in FIG. 1 as determined by powder X-ray diffractometry.Type: GrantFiled: February 22, 2011Date of Patent: February 11, 2014Assignees: Nippon Kayaku Co., Ltd., Meiji Seika Pharma Co., Ltd.Inventors: Kouki Tanigakiuchi, Mikio Sekiguchi, Hiroki Hotta, Shizuo Shimano, Akinori Morikawa, Kazumi Yamamoto, Nozomu Nakanishi, Nobuto Minowa, Takashi Watanabe
-
Publication number: 20140039171Abstract: Provided are: a novel monoalkylamino intermediate (I); and a production method for a compound represented by the formula (III), which is an animal antibacterial agent, via the novel monoalkylamino intermediate.Type: ApplicationFiled: February 28, 2012Publication date: February 6, 2014Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Kenichi Kurihara, Masaaki Mitomi, Nobuto Minoma
-
Publication number: 20140011757Abstract: The inventors of the present invention have succeeded in acquiring a compound having excellent antibacterial activities against pathogens of respiratory tract infections in animals through the use of josamycin as a lead scaffold.Type: ApplicationFiled: January 31, 2012Publication date: January 9, 2014Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Kenichi Kurihara, Masaaki Mitomi
-
Publication number: 20130345411Abstract: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.Type: ApplicationFiled: August 20, 2013Publication date: December 26, 2013Applicants: MICROBIAL CHEMISTRY RESEARCH FOUNDATION, MEIJI SEIKA PHARMA CO., LTD.Inventors: Yoshihiko KOBAYASHI, Yoshihisa AKIYAMA, Takeshi MURAKAMI, Nobuto MINOWA, Masaki TSUSHIMA, Yukiko HIRAIWA, Shoichi MURAKAMI, Mitsuhiro ABE, Kazushige SASAKI, Shigeru HOSHIKO, Toshiaki MIYAKE, Yoshiaki TAKAHASHI, Daishiro IKEDA